{"title":"阿昔替尼治疗女性红斑痤疮持续性红斑患者的实际经验","authors":"Yan Teng, Huiting Zhong, Youming Huang, Xiaohua Tao, Yibin Fan, Yong Yu","doi":"10.1177/1721727x241258794","DOIUrl":null,"url":null,"abstract":"Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.","PeriodicalId":11913,"journal":{"name":"European Journal of Inflammation","volume":"45 1","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-life experience of abrocitinib for the treatment of female patients with persistent erythema of rosacea\",\"authors\":\"Yan Teng, Huiting Zhong, Youming Huang, Xiaohua Tao, Yibin Fan, Yong Yu\",\"doi\":\"10.1177/1721727x241258794\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.\",\"PeriodicalId\":11913,\"journal\":{\"name\":\"European Journal of Inflammation\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Inflammation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1721727x241258794\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1721727x241258794","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real-life experience of abrocitinib for the treatment of female patients with persistent erythema of rosacea
Rosacea, a common and chronic skin disorder, presents with various cutaneous manifestations. The phenotype of rosacea determines the approach to treatment. Refractory rosacea with persistent erythema invariably necessitates pharmacologic agents. Herein, we report a case series on three female patients with persistent erythema of rosacea treated by abrocitinib, a JAK-1 inhibitor.
期刊介绍:
European Journal of Inflammation is a multidisciplinary, peer-reviewed, open access journal covering a wide range of topics in inflammation, including immunology, pathology, pharmacology and related general experimental and clinical research.